首站-论文投稿智能助手
典型文献
Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice
文献摘要:
INTRODUCTION Anti-resorptive treatment (ART) with agents such as bispho-sphonate (BPs) or denosumab (Dmab) is commonly practiced in patients with osteoporosis and bone metastatic diseases.1 In patients undergoing a long-term ART, a rare intraoral lesion called medication-related osteonecrosis of the jaw (MRONJ) may develop, which is clinically defined as exposed bone through intraoral and/or extraoral fistula that persists for more than 8 weeks without a history of radiation therapy.
文献关键词:
作者姓名:
Wen Du;Mengyu Yang;Terresa Kim;Sol Kim;Drake W.Williams;Maryam Esmaeili;Christine Hong;Ki-Hyuk Shin;Mo K.Kang;No-Hee Park;Reuben H.Kim
作者机构:
State Key Laboratory of Oral Diseases&National Clinical Research Center for Oral Diseases&Department of Prosthodontics,West China Hospital of Stomatology,Sichuan University,Chengdu,China;The Shapiro Family Laboratory of Viral Oncology and Aging Research,Los Angeles,USA;Section of Restorative Dentistry,UCLA School of Dentistry,Los Angeles,USA;Department of Orofacial Sciences,UCSF School of Dentistry,San Francisco,USA;UCLA Jonsson Comprehensive Cancer Center,Los Angeles,USA;David Geffen School of Medicine at UCLA,Los Angeles,USA
引用格式:
[1]Wen Du;Mengyu Yang;Terresa Kim;Sol Kim;Drake W.Williams;Maryam Esmaeili;Christine Hong;Ki-Hyuk Shin;Mo K.Kang;No-Hee Park;Reuben H.Kim-.Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice)[J].国际口腔科学杂志(英文版),2022(02):156-163
A类:
Anti,resorptive,bispho,sphonate,denosumab,Dmab
B类:
Indigenous,microbiota,protects,development,medication,related,osteonecrosis,induced,by,periapical,mice,INTRODUCTION,treatment,ART,agents,such,BPs,commonly,practiced,patients,osteoporosis,bone,metastatic,diseases,undergoing,long,term,rare,intraoral,lesion,called,jaw,MRONJ,may,which,clinically,defined,exposed,through,extraoral,fistula,that,persists,more,than,weeks,without,history,radiation,therapy
AB值:
0.635698
相似文献
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
Haoran Mu;Dongqing Zuo;Jie Chen;Zhigang Liu;Zhuo Wang;Liu Yang;Qihui Shi;Yingqi Hua-Shanghai Bone Tumor Institute and Department of Orthopedics,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Key Laboratory of Systems Biomedicine(Ministry of Education),Shanghai Center for Systems Biomedicine,Shanghai Jiao Tong University,Shanghai 200240,China;Shanghai Key Laboratory of Medical Epigenetics and the International Co-laboratory of Medical Epigenetics and Metabolism(MOST),Institutes of Biomedical Sciences,Fudan University,Shanghai 200032,China;Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer(SMHC)and Institute of Fudan-Minhang Academic Health System,Minhang Hospital,Fudan University,Shanghai 201199,China;Shanghai Engineering Research Center of Biomedical Analysis Reagents,Shanghai 201203,China
Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
Liu Zuojing;Zhu Shiwei;He Meibo;Li Mo;Wei Hui;Zhang Lu;Sun Qinghua;Jia Qiong;Hu Nan;Fang Yuan;Song Lijin;Zhou Chen;Tao Heqing;Y Kao John;Zhu Huaiqiu;Owyang Chung;Duan Liping-Department of Gastroenterology, Peking University Third Hospital, Haidian District, Beijing 100191, China;Department of Ultrasound, Peking University Third Hospital, Haidian District, Beijing 100191, China;Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China;Department of Biomedical Engineering, College of Engineering, Peking University, Beijing 100187, China;Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, 6520 MSRB I, SPC 5682, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA
Stratifin promotes renal dysfunction in ischemic and nephrotoxic AKI mouse models via enhancing RIPK3-mediated necroptosis
Fang Wang;Jia-nan Wang;Xiao-yan He;Xiao-guo Suo;Chao Li;Wei-jian Ni;Yu-ting Cai;Yuan He;Xin-yun Fang;Yu-hang Dong;Tian Xing;Ya-ru Yang;Feng Zhang;Xiang Zhong;Hong-mei Zang;Ming-ming Liu;Jun Li;Xiao-ming Meng;Juan Jin-Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,School of Pharmacy,Anhui Medical University,The Key Laboratory of Anti-inflammatory of Immune Medicines,Ministry of Education,Hefei 230032,China;Department of Pharmacy,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Hospital of Stomatology,Anhui Medical University,Key Laboratory of Oral Diseases Research of Anhui Province,Hefei 230032,China;Department of Pharmacy,Changzheng Hospital,Naval Medical University,Shanghai 200003,China;Department of Nephrology,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China
Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway
Yi-kuan Wu;Zheng-nan Ren;Sheng-long Zhu;Yun-zhou Wu;Gang Wang;Hao Zhang;Wei Chen;Zhao He;Xian-long Ye;Qi-xiao Zhai-State Key Laboratory of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Medicine,Jiangnan University,Wuxi 214122,China;College of Life Science,Northeast Agricultural University,Harbin 150038,China;National Engineering Research Center for Functional Food,Jiangnan University,Wuxi 214122,China;Shandong Key Laboratory of Endocrinology and Lipid Metabolism,Jinan 250021,China;School of Medicine,Shandong University,Jinan 250012,China;Ganjiang Chinese Medicine Innovation Center,Nanchang 330000,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。